Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

neutropenia - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

neutropenia

MONDO:0001475

Also known as:neutropenic disorder

Find Clinical TrialsTrials

Overview

A decrease in the number of neutrophils found in the blood.

Treatments2 FDA approved

Clinical Trials63 registered · 27 recruiting

Patient Orgs1 organizations · Neutropenia Support Association, Inc.

Diagnosis

Biomarker and diagnostic research for neutropenia has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for neutropenia, including FILGRASTIM (NEUPOGEN, approved 1991). An additional 3 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

63 clinical trials registered, 27 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and medical devices. Pipeline includes 9 PHASE4, 3 PHASE3, 9 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07066085](https://clinicaltrials.gov/study/NCT07066085)

Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 6:36 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Patient Advocacy Groups

View all PAGs →

Neutropenia Support Association, Inc.Primary Focus

USWebsite ↗

Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.

Are you a patient organization not listed here? Claim this page to be listed and embed this content on your site — free.

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of NEUPOGEN for managing neutropenia?
→Are any of the 63 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→How can I connect with Neutropenia Support Association, Inc. and other patient organizations for support?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Angiotensin 1-7	Angiotensin 1-7	Tarix Pharmaceuticals Ltd	2000	—	Designated
Leukine	sargramostim	Immunex Corporation	1990	1998	Designated (drug approved for other indication)
Granulocyte macrophage-colony stimulating factor	Granulocyte macrophage-colony stimulating factor	Schering Corporation	1989	—	Withdrawn

Research Type	Count	% of Total
Research summaries	42	23%
Disease patterns and progression	32	18%
Clinical study results	28	16%
Laboratory research	24	13%
Patient case studies	21	12%
Testing and diagnosis research	14	8%
Other research	9	5%
New treatment approaches	9	5%

Kisho

neutropenia

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Papiliotrema laurentii fungemia in a neutropenic patient with limited echinocandin susceptibility: a case report.

Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study

neutropenia

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Patient Support

Patient Advocacy Groups

Medical References

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Papiliotrema laurentii fungemia in a neutropenic patient with limited echinocandin susceptibility: a case report.

Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study